News | October 17, 2023
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Increased capability to produce medicines for challenging diseases including cancer
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing
InvaGen has received 5 inspectional observations in Form 483
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
Subscribe To Our Newsletter & Stay Updated
